Fulvestrant Plus Enzalutamide in ER+/Her2- Advanced Breast Cancer
Status:
Completed
Trial end date:
2020-04-10
Target enrollment:
Participant gender:
Summary
A phase 2 study to evaluate the tolerability and clinical activity of adding enzalutamide to
fulvestrant treatment in women with advanced breast cancer that are ER and/or PR positive and
Her2 normal.